

Dyne Therapeutics, Inc.
830 Winter Street
Waltham, MA 02451

January 19, 2021

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Abby Adams

Re: Dyne Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-252194
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Dyne Therapeutics, Inc. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-252194), so that it may become effective at 4:00 p.m. Eastern time on January 20, 2021, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request by telephone call to the staff of the U.S. Securities and Exchange Commission.

Please contact Stuart M. Falber of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, at (617) 526-6663, or in his absence, Scott Lunin at (212) 295-6388, to provide notice of effectiveness, or if you have any other questions regarding this matter.

[Remainder of Page Intentionally Left Blank]

Very truly yours,

DYNE THERAPEUTICS, INC.

By: /s/ Joshua Brumm

Name: Joshua Brumm

Title: President and Chief Executive Officer

Signature Page to Acceleration Request